For the fourth time since 2020, Purdue Pharma has announced refunds to 340B covered entities for overcharges. Purdue, which pled guilty in November in federal court to fraud and kickback charges related to its role in fueling the national opioid-abuse epidemic, said it would be providing refunds or credits for the painkillers OxyContin, Butrans and Hysingla as well as for the insomnia drug Intermezzo. The drugs were either produced by Purdue or its subsidiary Avrio Health.
The refunds, which were posted on the U.S Health Resources and Services Administration’s Office of Pharmacy Affairs web site, will cover all of calendar year 2019. Purdue said in its notice that Apexus would handle refunds and credits to covered entities through its drug wholesalers.
For the fourth time since 2020, Purdue Pharma has announced refunds to 340B covered entities for overcharges. Purdue, which pled guilty in November in federal court to fraud and kickback charges related to its role in fueling the national opioid-abuse epidemic, said it would be providing refunds or credits for the painkillers OxyContin, Butrans and Hysingla as well as for the insomnia drug Intermezzo. The drugs were either produced by Purdue or its subsidiary Avrio Health.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
